Skip to content

Metabolic Flexibility to Predict Lifestyle Interventions Outcomes

Whole Body and Gut Microbiome Metabolic Flexibility to Predict Lifestyle Intervention Outcomes

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06329349
Acronym
MEPHISTO
Enrollment
30
Registered
2024-03-25
Start date
2024-01-02
Completion date
2026-04-01
Last updated
2024-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

obesity, metabolic flexibility, metabolomic, exercise, diet

Brief summary

Weight loss is a cornerstone of diabetes (T2D) management, yet in clinical practice, its delivery is limited by its perceived burdensome nature and variability in response. Personalization of the interventions to increase their success rate is an unmet clinical need. The proposed project MEPHISTO (Whole body and gut microbiome metabolic flexibility to predict lifestyle intervention outcomes) would aim to identify predictive features related to successful weight loss upon sequential exercise and diet intervention in people living with obesity. To this end, the study aims to conduct a clinical trial where the investigators would implement state-of-the-art physiological phenotyping of metabolic flexibility at the whole-body level and at the level of the gut in persons with obesity before and after exercise and diet + exercise intervention to identify predictive signatures of successful weight loss

Detailed description

Among the influential determinants impacting the efficacy and health outcomes of an intervention is an individual's level of metabolic flexibility (MetFlex). MetFlex denotes the body's capacity to adapt in response to alterations in metabolic demands and nutrient availability. Impaired MetFlex is evident in conditions such as obesity and diabetes, yet it may be ameliorated through lifestyle interventions such as exercise training or caloric restriction similar to improvements in insulin sensitivity. However, MetFlex has not been studied as a potential mechanism associated with successful weight loss. The decline in MetFlex, i.e. the limited cellular/tissue ability to manage excess or deficiency in energy substrates leads to compromised mitochondrial function and excessive lipid accumulation in ectopic tissues, resulting in metabolic disorders such as T2D or metabolic syndrome. Another potential player predicting an individual's capacity to respond to lifestyle interventions is the gut microbiota (gut microbiome and metabolome, MIME). It was repeatedly shown to be among the most important sources of inter-individual variability when it comes to the development of obesity and responsiveness to dietary intervention The microbiome does not only influence host physiology directly, e.g. through contact with immune cells, but also through the vast array of metabolites produced, i.e. the microbiota-derived metabolome. The composition of the gut microbiota and the microbiota-derived metabolome is largely shaped by the host's diet, as this represents the main source of substances and energy for the microbiota. It is therefore striking that published studies to date have yielded rather inconsistent results regarding dietary interventions to alter gut microbiota composition. The discrepancy can be explained by the large variability of individual microbiomes at the beginning of the intervention, and similarly the baseline MIME signature significantly determines weight loss success. Here the investigators present a complex project to investigate whether whole body and gut MetFlex can be further explored and used as ex-ante predictors of successful weight loss following exercise and dietary interventions, thus providing proof of concept and paving the way to personalized lifestyle interventions.

Interventions

OTHERExercise

12 weeks, 3 times a week of progressive endurance aerobic exercise (150 to 400kcal AEE per session)

OTHERCombined Exercise + Diet

12 weeks, 25% caloric reduction, based on PMID: 37069434

Sponsors

Ministry of Health, Czech Republic
CollaboratorOTHER_GOV
EXCELES LX22NPO5104, CarDia
CollaboratorUNKNOWN
Charles University, Czech Republic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

2:1 randomized cross-over

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* BMI\>30 * age 25-45 years

Exclusion criteria

* active cancer * diabetes (medical history, fasting glycemia \>7.6 and/or 2hOGTT glycemia \>11.1) * uncontrolled endocrine diseases * corticosteroid therapy * immune-suppressive therapy * pregnancy * breastfeeding

Design outcomes

Primary

MeasureTime frameDescription
Change in metabolic flexibility (MetFlex (ΔRQ 200-0))18 monthschange in metabolic flexibility measured as ΔRQ (respiratory quotient) during glucose clamp
Change in insulin sensitivity18 monthschange in insulin sensitivity measured as glucose infusion rate (GIR) during glucose clamp

Secondary

MeasureTime frameDescription
Insulin sensitivity relate to primary outcomes changes18 monthsGIR positively relate to weight loss.
HbA1c relate to primary outcomes changes18 monthsHbA1c positively relate to weight loss.
Glucose tolerance relate to primary outcomes changes18 monthsfasting/2h oral glucose tolerance test glycemia positively relate to weight loss.

Other

MeasureTime frameDescription
Microbiome composition relate to weight loss: exploratory outcome18 monthsChange in microbiome composition in fecal samples upon the intervention is a component of successful weight loss and/or metabolic adaptation
Metabolomic signatures relate to weight loss: exploratory outcome18 monthsChange in metabolomic signatures in fecal samples upon the intervention is a component of successful weight loss and/or metabolic adaptation

Countries

Czechia

Contacts

Primary ContactJan Gojda, PhD
jan.gojda@lf3.cuni.cz+420267163031
Backup ContactJana Potočková
potocko@fnkv.cz+420267163031

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026